A year after the first samRNA vaccine approval, experts say similar vaccines in development are likely to face scientific and ...
In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...
The Cambridge-GSK Translational Immunology Collaboration builds on an existing scientific relationship between the biopharma company and the university, with the aim of improving outcomes for patients ...
Colossal, the company founded to try to restore the mammoth to the Arctic tundra, has also decided to tackle a number of ...
The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...
Barchart on MSN23h
Earnings Preview: What to Expect From Moderna's ReportBased in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a leading biotechnology company that develops messenger RNA (mRNA) ...
European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapyPatent applications for the ...
Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such ...
Hosted on MSN1d
A Novel Regulator of RNA Processing in Alzheimer's DiseaseA research team from the University of Barcelona's Institute of Neurosciences described a novel molecular mechanism that ...
Altered RNA processing is highly damaging to neurons, adding a new toxic component to the evolution of AD. Currently, the ...
Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback